Since the expansion of the war in Ukraine in February 2022, more than 14 million people have been internally displaced or forced to flee to neighboring countries as refugees, often losing access to health care. HIV and TB prevention and diagnosis services have been disrupted, and many people with HIV and TB have been forced to interrupt their lifesaving treatment. The war has left hundreds of thousands of people without electricity or water supplies, and almost half of the population is in need of humanitarian assistance.

Educational materials designed for community-based and civil society organizations to use to advocate for and teach people about TB preventive treatment.

The Office of HIV/AIDS Network Coordination (HANC) and the TB Trials Consortium Community Research Advisors Group hosted a webinar on 22 February 2024 focused on TB vaccines.

WHO’s latest data has highlighted the significant challenge tuberculosis continues to pose in the Philippines, revealing that in 2022, an alarming 737,000 individuals contracted TB. This translates to a new case every 43 seconds, underscoring the urgency of the situation.

Tuberculosis or TB, one of the top infectious diseases responsible for mortality worldwide, is one of those diseases that majorly affects those in the lower socio-economic group. 

While progress has been made toward the 2030 goal to end TB, gaps persist between aspirations and the current situation.

Médecins Sans Frontières (MSF) Access Campaign will host a webinar on 5 March 2024 to provide an update about the next phase of escalation of the Time for $5 Campaign.

A consensus statement provides a framework for ensuring that pregnant and breastfeeding women and persons are better served by TB research and can fully benefit from scientific advancements in the prevention and treatment of TB.

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO in Haiti. Second-line medications are those that are given when one or more of the drugs given first for the disease are not effective. The research could have implications for shortening the duration of treatment for drug-resistant TB, which currently requires medications for up to 2 years, while those with drug-sensitive TB complete treatment in about 6 months. 

The Stop TB Partnership releases the campaign toolkit for this year’s 'Yes! We Can End TB' World TB Day campaign on 24 March 2024.